A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2017
At a glance
- Drugs HMPL 523 (Primary)
- Indications B cell lymphoma; Haematological malignancies
- Focus Adverse reactions
- Sponsors Hutchison MediPharma
- 27 Dec 2016 The first patient has been dosed in this trial, as reported by a Chi-Med media release.
- 27 Dec 2016 Status changed from not yet recruiting to recruiting,as reported by a Chi-Med media release.
- 09 Aug 2016 New trial record